Journal article
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study
NPJ breast cancer, Vol.2(1), 16017
2016
DOI: 10.1038/npjbcancer.2016.17
PMCID: PMC5515329
PMID: 28721379
Abstract
The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute collaborated with Genomic Health and 14 population-based registries in the the Surveillance, Epidemiology, and End Results (SEER) Program to electronically supplement cancer surveillance data with Recurrence Score results. The prespecified primary analysis cohort was 40-84 years of age, and had node-negative, HR+, HER2-negative, nonmetastatic disease diagnosed between January 2004 and December 2011 in the entire SEER population, and Recurrence Score results (
Details
- Title: Subtitle
- Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study
- Creators
- Valentina I Petkov - National Cancer Institute, Bethesda, MD, USADave P Miller - Genomic Health, Inc., Redwood City, CA, USANadia Howlader - National Cancer Institute, Bethesda, MD, USANathan Gliner - Genomic Health, Inc., Redwood City, CA, USAWill Howe - IMS, Inc., Calverton, MD, USANicola Schussler - IMS, Inc., Calverton, MD, USAKathleen Cronin - National Cancer Institute, Bethesda, MD, USAFrederick L Baehner - University of California, San Francisco, CA, USARosemary Cress - Public Health Institute, Cancer Registry of Greater California, Sacramento, CA, USADennis Deapen - University of Southern California, Los Angeles, CA, USASally L Glaser - Stanford Cancer Institute, Stanford, CA, USABrenda Y Hernandez - University of Hawaii Cancer Center, Honolulu, HI, USACharles F Lynch - University of Iowa, EpidemiologyLloyd Mueller - Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USAAnn G Schwartz - Karmanos Cancer Institute, Wayne State University, Detroit, MI, USAStephen M Schwartz - Cancer Surveillance System, Fred Hutchinson Cancer Research Center, Seattle, WA, USAAntoinette Stroup - Cancer Institute of New Jersey, New Brunswick, NJ, USACarol Sweeney - University of UtahThomas C Tucker - University of Kentucky, Markey Cancer Center, Lexington, KY, USAKevin C Ward - Emory University, Atlanta, GA, USACharles Wiggins - New Mexico Tumor Registry, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USAXiao-Cheng Wu - Louisiana State University Health Sciences Center, New Orleans, LA, USALynne Penberthy - National Cancer Institute, Bethesda, MD, USASteven Shak - Genomic Health, Inc., Redwood City, CA, USA
- Resource Type
- Journal article
- Publication Details
- NPJ breast cancer, Vol.2(1), 16017
- DOI
- 10.1038/npjbcancer.2016.17
- PMID
- 28721379
- PMCID
- PMC5515329
- NLM abbreviation
- NPJ Breast Cancer
- ISSN
- 2374-4677
- eISSN
- 2374-4677
- Publisher
- United States
- Grant note
- HHSN261201300015C / CCR NIH HHS HHSN261201300009C / NCI NIH HHS P30 CA015704 / NCI NIH HHS HHSN261201300031C / NCI NIH HHS HHSN261201000034C / NCI NIH HHS P30 CA086862 / NCI NIH HHS P30 CA118100 / NCI NIH HHS HHSN261201000131C / NCI NIH HHS HHSN261201300011I / NCI NIH HHS HHSN261201300013C / NCI NIH HHS HHSN261201300020C / NCI NIH HHS HHSN261201300016I / NCI NIH HHS HHSN261201000035C / NCI NIH HHS U58 DP003862 / NCCDPHP CDC HHS HHSN261201000140C / NCI NIH HHS HHSN261201300020I / NCI NIH HHS P30 CA022453 / NCI NIH HHS U58 DP003907 / NCCDPHP CDC HHS HHSN261201300011C / CCR NIH HHS HHSN261201000035I / NCI NIH HHS HHSN261201300016C / NCI NIH HHS
- Language
- English
- Date published
- 2016
- Academic Unit
- Epidemiology
- Record Identifier
- 9984003798102771
Metrics
139 Record Views